Bloomage Biotechnology Corp Ltd
SSE:688363

Watchlist Manager
Bloomage Biotechnology Corp Ltd Logo
Bloomage Biotechnology Corp Ltd
SSE:688363
Watchlist
Price: 62.5 CNY -4.21% Market Closed
Market Cap: 30.1B CNY
Have any thoughts about
Bloomage Biotechnology Corp Ltd?
Write Note

Bloomage Biotechnology Corp Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bloomage Biotechnology Corp Ltd
Cash & Cash Equivalents Peer Comparison

Comparables:
6160
603392
002252
300122
300896

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Bloomage Biotechnology Corp Ltd
SSE:688363
Cash & Cash Equivalents
ÂĄ623.6m
CAGR 3-Years
-29%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash & Cash Equivalents
ÂĄ15B
CAGR 3-Years
33%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash & Cash Equivalents
ÂĄ3.8B
CAGR 3-Years
75%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Cash & Cash Equivalents
ÂĄ1.9B
CAGR 3-Years
-1%
CAGR 5-Years
13%
CAGR 10-Years
7%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash & Cash Equivalents
ÂĄ5.6B
CAGR 3-Years
3%
CAGR 5-Years
82%
CAGR 10-Years
19%
Imeik Technology Development Co Ltd
SZSE:300896
Cash & Cash Equivalents
ÂĄ2.4B
CAGR 3-Years
-11%
CAGR 5-Years
56%
CAGR 10-Years
N/A

See Also

What is Bloomage Biotechnology Corp Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
623.6m CNY

Based on the financial report for Jun 30, 2024, Bloomage Biotechnology Corp Ltd's Cash & Cash Equivalents amounts to 623.6m CNY.

What is Bloomage Biotechnology Corp Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-2%

Over the last year, the Cash & Cash Equivalents growth was -30%. The average annual Cash & Cash Equivalents growth rates for Bloomage Biotechnology Corp Ltd have been -29% over the past three years , -2% over the past five years .

Back to Top